Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 6/20 | 0.36 |
| ▸ | NOS1 | P29475 | 5/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622982 | 0.84 | ASIC3 (0.40) | IDH1ASIC3NOS3NOS1BRS3 | |
| SCHEMBL10130760 | 0.79 | IDH1 (0.46) | IDH1ASIC3NOS3NOS1LARS1 | |
| SCHEMBL4309177 | 0.78 | ASIC3 (0.38) | IDH1ASIC3NOS3NOS1SRC | |
| SCHEMBL13437308 | 0.78 | ALDH1A1 (0.50) | TRPM8 | |
| SCHEMBL13615884 | 0.78 | ASIC3 (0.40) | IDH1ASIC3NOS3NOS1MAP3K5 | |
| SCHEMBL13615811 | 0.77 | IDH1 (0.43) | IDH1ASIC3NOS3NOS1LARS1 | |
| SCHEMBL13629736 | 0.75 | SRC (0.43) | IDH1ASIC3NOS3NOS1MAP3K5 | |
| SCHEMBL13174733 | 0.75 | FBP1 (0.43) | — | |
| SCHEMBL13615819 | 0.72 | IDH1 (0.46) | IDH1ASIC3NOS3NOS1LARS1 | |
| SCHEMBL14409016 | 0.72 | CYP11B1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDH1 1333/4885ASIC3 1928/4885NOS3 2927/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | IDH1 1333/4885ASIC3 1928/4885NOS3 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.